Seeking Alpha

Equity markets remain under pressure on Monday as investors await the start of the fourth-quarter earnings season for guidance on whether the rally of November and December could be resumed in January. Last week was the first down week for U.S. stocks following nine-consecutive weeks of gains for...

Deere & Company reports its fourth-quarter earnings on Nov. 22 against the backdrop of a share price that has fallen 15% in the past four months. But could this be an opportunity to buy? Analysts polled by Zacks Investment Research have forecast Deere & Company (NYSE:DE) earnings per share...

“If you want to build a service, engage and be humble,” said J. Mintzmyer, founder of Value Investor’s Edge.  "Everyone makes mistakes. Be humble about that and be approachable,” he said Friday at the 2022 Fintwit Conference presented by Benzinga and...

In partnership with Lupton Capital, Benzinga is hosting the FinTwit Conference on May 13-14, 2022 at the ARIA Resort & Casino in Las Vegas. In attendance will be leaders in trading and investing that will speak on ways to navigate volatility, as well as protect and grow capital in personalized...

Papa John's International, Inc's (NASDAQ: PZZA) founder and former CEO Papa John Schnatter is bearish on the company he founded and thinks it is overvalued at 56 times earnings. What Happened: Schnatter has given the reasons for his bearish view in a Seeking Alpha article, which was in...

InVitae Corp (NYSE: NVTA) shares have had a somewhat volatile week of trading after short seller allegations against the company prompted a bullish analyst to defend InVitae’s model. What Happened On Oct. 11, a short seller article published on Seeking Alpha accused InVitae of being the...

Medical device company Soliton, Inc. (NASDAQ: SOLY) reacted Friday to a blog post calling the firm a "PR machine" and addressed whether it can achieve Food and Drug Administration clearance to market its new Rapid Acoustic Pulse technology. RAP technology has the ...

Biogen Inc (NASDAQ: BIIB) to acquire gene therapy company Nightstar Therapeutics PLC (NASDAQ: NITE). Roche Holdings AG Basel ADR (OTC: RHHBY) agrees to buy Spark Therapeutics Inc (NASDAQ: ONCE). Sarepta Therapeutics Inc (NASDAQ: SRPT) exercises option to buy Myonexus Therapeutics for $165...

Opposition to the buyout deal Bristol-Myers Squibb Co (NYSE: BMY) negotiated with Celgene Corporation (NASDAQ: CELG) in January is rising and could potentially impede the M&A momentum seen in the biotech space this year. What Happened Wellington Management Co, which owns an 8.3-percent stake...

Seeking Alpha has announced a major acquisition of CressCap Investment Research, a move that will change the type of information investors can find on the news platform.   What Happened On Wednesday, Seeking Alpha announced it has acquired CressCap, a quantitative analytics and data...

Just a decade ago, electric cars seemed like a futuristic vision. Now, there's always a chance of looking to one's left a red light and spotting a Tesla Inc (NASDAQ: TSLA) or even a Solo. One car company is taking a different approach in the electric race for a cleaner future: ...

At a time when tech stocks have entered a rough patch amid broader market volatility, NVIDIA Corporation (NASDAQ: NVDA) is gearing up to release its fiscal 2018 third-quarter results Thursday, Nov. 15 after the market close. The Headline Numbers Analysts, on average, expect the company to report...

Robinhood is pushing back following allegations by a Seeking Alpha contributor that the company sells its order flow to exchanges at a higher rate than other discount brokerages, suggesting that Robinhood customers potentially receive lower execution quality and worse execution prices....

Farmland Partners Inc (NYSE: FPI) dropped 39 percent Wednesday on negative rumors about its loan program, solvency, valuation and reliance on external sources of capital, among other factors. The Analyst B. Riley FBR analyst Craig Kucera upgraded Farmland Partners from Neutral to Buy and cut...

AcelRx Pharmaceuticals Inc (NASDAQ: ACRX) shares have been on a tear and are trading near a two-year high after speculation started doing the rounds that its pain treatment candidate DSUVIA is poised to get early approval. About 3.25 million shares exchanged hands, roughly 2.5 times the average...